FIELD: medicine.
SUBSTANCE: invention relates to biotechnology, specifically to immunogenic UBE2T epitopes, and can be used in medicine for treating a patient suffering from cancer.
EFFECT: obtained are modified epitope UBE2T peptides binding to HLA-A*2402 or HLA-A*0201 and possess a higher ability to induce cytotoxic T lymphocytes (CTL) than the wild-type epitope UBE2T peptide.
12 cl, 8 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
| KNTC2 PEPTIDES AND VACCINES CONTAINING THE SAME | 2014 |
|
RU2671395C2 |
| HJURP PEPTIDES AND VACCINES CONTAINING THEM | 2011 |
|
RU2570560C2 |
| FOXP3 PEPTIDE VACCINE | 2007 |
|
RU2473557C2 |
| MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THEM | 2012 |
|
RU2612905C2 |
| PEPTIDE VACCINES FOR CANCER EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES | 2007 |
|
RU2469044C2 |
| TEM8 PEPTIDES AND VACCINES CONTAINING THEM | 2008 |
|
RU2498993C2 |
| EPITOPE WDRPUH PEPTIDES AND VACCINES, CONTAINING THEM | 2009 |
|
RU2514386C2 |
| MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THEM | 2009 |
|
RU2496787C2 |
| NEIL3 PEPTIDES AND VACCINES INCLUDING SAME | 2010 |
|
RU2600888C2 |
